ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab

Bernardo Stefanini; Claudia Angela Maria Fulgenzi; Bernhard Scheiner; James Korolewicz; Jaekyung Cheon; Naoshi Nishida; Celina Ang; Thomas U. Marron; Linda Y. Wu; Anwaar Saeed; Brooke Wietharn; Lorenza Rimassa; Angelo Pirozzi; Antonella Cammarota; Tiziana Pressiani; Matthias Pinter; Lorenz Balcar; Yi‐Hsiang Huang; Aman Mehan; Samuel Phen; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Adel Samson; Peter R. Galle; Masatoshi Kudo; Giulia Francesca Manfredi; Ciro Celsa; Nichola Awosika; Alessio Cortellini; Amit G. Singal; Rohini Sharma; Hong Jae Chon; Francesco Tovoli; Fabio Piscaglia; David J. Pinato; Antonio D’Alessio

doi:10.2147/jhc.s462701

Related publications

Article2023

The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, Naoshi Nishida, Celina Ang, Thomas U. Marron, Linda Y. Wu, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Matthias Pinter, Lorenz Balcar, Yi‐Hsiang Huang, Aman Mehan, Samuel Phen, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schoenlein, Johann von Felden, Kornelius Schulze, Henning Wege, Adel Samson, Peter R. Galle, Masatoshi Kudo, Alessio Cortellini, Amit G. Singal, Lorenza Rimassa, Rohini Sharma, Hong Jae Chon, David J. Pinato

Article2020

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

Masatoshi Kudo, Peter R. Galle, Giovanni Brandi, Yoon‐Koo Kang, Chia-Jui Yen, Richard S. Finn, Josep M. Llovet, Éric Assenat, Philippe Merle, Stephen L. Chan, Daniel H. Palmer, Masafumi Ikeda, Tatsuya Yamashita, Arndt Vogel, Yi‐Hsiang Huang, Paolo Abada, Reigetsu Yoshikawa, Kenta Shinozaki, Chunxiao Wang, Ryan C. Widau, Andrew X. Zhu

JHEP Reports

Article2017

Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Yohei Koizumi, Yoichi Hiasa, Kazuto Tajiri, Hidenori Toyoda, Toshifumi Tada, Hironori Ochi, Koji Joko, Noritomo Shimada, Akihiro Deguchi, Toru Ishikawa, Michitaka Imai, Kunihiko Tsuji, Kojiro Michitaka

Article2022

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron, Linda Y. Wu, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Andrea Napolitano, Yi‐Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger,

Article2017

Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial

María Asunción Esteve‐Pastor, José Miguel Rivera‐Caravaca, Alena Shantsila, Vanessa Roldán, Professor Gregory Lip, Francisco Marı́n